Abstract
Pharmaceutical companies in the US and Europe are recognising the various benefits of using pre-launch named patient programmes (NPPs) as an essential component of their global market access strategy to optimise product launches, produce real-life forecasting data and deliver early access to patients. This paper presents results of the first study to assess the financial impact of using a pre-launch NPP on a product launch. A multivariate analysis demonstrated that implementing pre-launch NPPs had a significant effect on the cash market share of a drug within the first year of launch. Specifically, in a particular drug market, there was a 1.362 times higher odds of spending $1 on a drug that participated in an NPP compared with a drug that did not use NPP. The paper also discusses the various regulatory and practical challenges companies face when implementing NPPs across Europe, and the increasing use of specialist management organisations to coordinate these tailored European programmes.
Get full access to this article
View all access options for this article.